Krka d. d - Asset Resilience Ratio
Krka d. d (KRK) has an Asset Resilience Ratio of 10.28% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Krka d. d to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how Krka d. d's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Krka d. d balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Krka d. d's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Krka d. d to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł342.81 Million | 10.28% |
| Total Liquid Assets | zł342.81 Million | 10.28% |
Asset Resilience Insights
- Moderate Liquidity: Krka d. d has 10.28% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Krka d. d Industry Peers by Asset Resilience Ratio
Compare Krka d. d's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Shenzhen Kangtai Biological Products Co Ltd
SHE:300601 |
Drug Manufacturers - Specialty & Generic | 12.99% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
|
ChengDa Pharmaceuticals Co. Ltd.
SHE:301201 |
Drug Manufacturers - Specialty & Generic | 32.14% |
Annual Asset Resilience Ratio for Krka d. d (2010–2025)
The table below shows the annual Asset Resilience Ratio data for Krka d. d.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 8.46% | zł257.41 Million ≈ $70.84 Million |
zł3.04 Billion ≈ $837.79 Million |
-0.12pp |
| 2024-12-31 | 8.58% | zł244.34 Million ≈ $67.25 Million |
zł2.85 Billion ≈ $784.09 Million |
+6.04pp |
| 2023-12-31 | 2.53% | zł70.02 Million ≈ $19.27 Million |
zł2.76 Billion ≈ $760.77 Million |
+0.65pp |
| 2022-12-31 | 1.89% | zł50.70 Million ≈ $13.95 Million |
zł2.69 Billion ≈ $739.64 Million |
-4.18pp |
| 2021-12-31 | 6.07% | zł153.96 Million ≈ $42.37 Million |
zł2.54 Billion ≈ $698.41 Million |
+5.67pp |
| 2020-12-31 | 0.40% | zł8.97 Million ≈ $2.47 Million |
zł2.24 Billion ≈ $615.25 Million |
+0.30pp |
| 2019-12-31 | 0.10% | zł2.17 Million ≈ $598.32K |
zł2.18 Billion ≈ $601.24 Million |
-0.05pp |
| 2018-12-31 | 0.15% | zł2.92 Million ≈ $803.63K |
zł1.99 Billion ≈ $546.32 Million |
+0.64pp |
| 2017-12-31 | -0.50% | zł-9.54 Million ≈ $-2.63 Million |
zł1.92 Billion ≈ $528.17 Million |
-0.50pp |
| 2016-12-31 | 0.00% | zł77.00K ≈ $21.19K |
zł1.91 Billion ≈ $526.08 Million |
0.00pp |
| 2015-12-31 | 0.00% | zł79.00K ≈ $21.74K |
zł1.81 Billion ≈ $497.92 Million |
-0.03pp |
| 2014-12-31 | 0.03% | zł575.00K ≈ $158.25K |
zł1.80 Billion ≈ $494.21 Million |
-0.01pp |
| 2013-12-31 | 0.05% | zł792.00K ≈ $217.97K |
zł1.76 Billion ≈ $484.35 Million |
+0.00pp |
| 2012-12-31 | 0.04% | zł679.00K ≈ $186.87K |
zł1.63 Billion ≈ $447.70 Million |
+0.00pp |
| 2011-12-31 | 0.04% | zł602.00K ≈ $165.68K |
zł1.53 Billion ≈ $422.19 Million |
0.00pp |
| 2010-12-31 | 0.04% | zł653.00K ≈ $179.72K |
zł1.49 Billion ≈ $409.58 Million |
-- |
About Krka d. d
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, an… Read more